Trial Profile
To investigate the treatment outcomes of Pembrolizumab or Nivolumab in patients with Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Oct 2016
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 08 Oct 2016 New trial record